Mid Cap Movers (CFN, AKAM, QCOR, NFLX, RF)


CareFusion Corporation (NYSE: CFN) plunged 8.95% to $23.20 in the early hour after the company expects to report adjusted second-quarter earnings of $0.41 to $0.45 a share. Analysts estimate the company to report second-quarter earnings $0.46 a share.

Akamai Technologies, Inc. (NASDAQ: AKAM) decreased 1.56% to $32.25 in the morning hour after the company introduced technology advancements for the rapidly evolving online entertainment industry in the areas of security and delivery, as well broader support for emerging business models.

Questcor Pharmaceuticals, Inc.  (Public, NASDAQ:QCOR) climbed 8.63% to $42.31 in the early hour after the company announced the preliminary operating metrics for the fourth quarter 2011. Operating expenses for the fourth quarter are estimated to be in the range of 20-30% higher than the third quarter of 2011, reflecting the Company’s increased investment in sales and marketing and R&D activities for Acthar.

Netflix, Inc. (NASDAQ: NFLX) increased 3.64% to $89.38 in the early hour after the company launched in the United Kingdom and Ireland, offering instant and unlimited access to a broad range of entertainment for the low monthly price of 5.99 Pounds Sterling in the UK and euro 6.99 in Ireland.

Regions Financial Corporation (NYSE: RF) gained 3.17% to $4.55 in the early hour after the company said it is close to a deal to sell its Morgan Keegan & Co. unit to Raymond James Financial Inc. or Stifel Financial Corp. for roughly $1 billion.

Disclaimer:

The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.

Tagged with: | | | |
Our Research Report on AKAM is now available. Don´t Trade AKAM until you Read our FREE FULL REPORT. Click Here